Pharmaceutical Technology, January 2011 Issue (PDF)

Transformations in Drug Development for Cell and Gene Therapies

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

Related Content

Christopher Cole

Transformations in Drug Development for Cell and Gene Therapies

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.